Novartis: Psoriasis trials

The registry lists 68 Psoriasis studies with Novartis as lead sponsor. 3 are open to participants now and 41 have results posted.

Phase 1 7Phase 2 10Phase 3 30Phase 4 6No phase 17(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic ArthritisRecruitingNCT07801495Phase 2
• A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLDRecruitingNCT07683065
• Modifying PEST for Psoriatic Arthritis ScreeningRecruitingNCT06382051Not applicable
• A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis (ASAP Study)CompletedNCT05758402Not applicableResults posted
• Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT03589885Phase 3Results posted
• Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to UstekinumabCompletedNCT03553823Phase 2Results posted
• Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque PsoriasisCompletedNCT03504852Phase 3Results posted
• Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic SyndromeCompletedNCT03440736Phase 4Results posted
• Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type PsoriasisCompletedNCT03066609Phase 3Results posted
• Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis PatientsCompletedNCT03055494Phase 4Results posted
• Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque PsoriasisCompletedNCT03020199Phase 4Results posted
• Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque PsoriasisCompletedNCT02826603Phase 3Results posted
• Study of Secukinumab With 2 mL Pre-filled SyringesCompletedNCT02748863Phase 3Results posted
• Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT02690701Phase 4Results posted
• Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe PsoriasisCompletedNCT02595970Phase 3Results posted
• Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With SecukinumabCompletedNCT02559622Phase 3Results posted
• Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine ACompletedNCT02547714Phase 4Results posted
• Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.CompletedNCT02474082Phase 3Results posted
• Pediatric Study in Children and Adolescents With Severe Plaque PsoriasisCompletedNCT02471144Phase 3Results posted
• Plaque Psoriasis Efficacy and Safety With SecukinumabCompletedNCT02409667Phase 3Results posted
• Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional BiomarkersCompletedNCT02362789Phase 3Results posted
• Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp PsoriasisCompletedNCT02267135Phase 3Results posted
• Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and HumiraCompletedNCT02016105Phase 3Results posted
• Palmoplantar Pustular Psoriasis Efficacy and Safety With SecukinumabCompletedNCT02008890Phase 3Results posted
• Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.CompletedNCT01961609Phase 3Results posted
• Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)CompletedNCT01952015Phase 3Results posted
• Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and EnbrelCompletedNCT01891864Phase 3Results posted
• Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail PsoriasisCompletedNCT01807520Phase 3Results posted
• 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type PsoriasisCompletedNCT01640951Phase 3Results posted
• Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)CompletedNCT01636687Phase 3Results posted
• First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 WeeksCompletedNCT01555125Phase 3Results posted
• Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With SecukinumabCompletedNCT01544595Phase 3Results posted
• Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis PatientsCompletedNCT01537432Phase 2Results posted
• Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type PsoriasisCompletedNCT01412944Phase 3Results posted
• Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose RegimensCompletedNCT01406938Phase 3Results posted
• Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 YearCompletedNCT01365455Phase 3Results posted
• Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type PsoriasisCompletedNCT01358578Phase 3Results posted
• AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe PsoriasisCompletedNCT01132612Phase 2Results posted
• Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious UveitisTerminatedNCT01090310Phase 3Results posted
• A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type PsoriasisCompletedNCT01071252Phase 2Results posted
• AIN457 Regimen Finding Study in Patients With Moderate to Severe PsoriasisCompletedNCT00941031Phase 2Results posted
• Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type PsoriasisCompletedNCT00805480Phase 2Results posted
• A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque PsoriasisCompletedNCT00669916Phase 1/2Results posted
• Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque PsoriasisCompletedNCT00438360Phase 3Results posted
• A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in BrazilTerminatedNCT06715254
• Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab EnvironmentCompletedNCT06666114
• Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK RegistryCompletedNCT06172426
• Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With PsoriasisActive, not recruitingNCT06142357
• A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world SettingCompletedNCT05787236
• Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque PsoriasisCompletedNCT05650060
• Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With PsoriasisCompletedNCT05513014
• A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in ChinaCompletedNCT05388916
• An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data SourceCompletedNCT05368818
• Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT05344482
• Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)CompletedNCT05320159
• A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in ChinaCompletedNCT04894890
• An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal UltrasoundWithdrawnNCT04488185Phase 4
• Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish PopulationWithdrawnNCT02795416Phase 3
• A Registry of Patients With Moderate to Severe Plaque PsoriasisCompletedNCT02786186
• Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque PsoriasisCompletedNCT02607774Phase 1
• Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.WithdrawnNCT01900782Phase 3
• Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in PsoriasisCompletedNCT01828086Phase 1
• Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic PatientsCompletedNCT01539915Phase 1
• Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mgCompletedNCT01539213Phase 1
• Safety and Efficacy of BFH772 in Psoriasis PatientsCompletedNCT00987870Phase 1/2
• A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque PsoriasisCompletedNCT00885196Phase 2
• Study of the Safety, Tolerability and Efficacy of BCT194 in Healthy Volunteers and Patients With Psoriasis.CompletedNCT00417820Phase 1
• Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type PsoriasisCompletedNCT00098189